Nigel H. Greig mostly deals with Internal medicine, Endocrinology, Neuroscience, Neuroprotection and Alzheimer's disease. His Internal medicine research focuses on Cholinergic in particular. His work deals with themes such as Acetylcholinesterase and Neurotrophin, which intersect with Endocrinology.
His biological study spans a wide range of topics, including Tumor necrosis factor alpha, Neuroinflammation, Pharmacology, Mitochondrion and Traumatic brain injury. His research integrates issues of Dopaminergic, Dopamine, Neurodegeneration and Parkinson's disease in his study of Neuroprotection. The concepts of his Alzheimer's disease study are interwoven with issues in Downregulation and upregulation and Dementia.
Nigel H. Greig mainly focuses on Pharmacology, Internal medicine, Endocrinology, Neuroscience and Disease. His Pharmacology research is multidisciplinary, incorporating elements of Acetylcholinesterase and In vivo. His studies deal with areas such as Diabetes mellitus and Oncology as well as Internal medicine.
His Endocrinology research includes themes of Agonist, Receptor and Amyloid beta. In his study, Drug development is strongly linked to Intensive care medicine, which falls under the umbrella field of Disease. His Alzheimer's disease study combines topics in areas such as Immunology and Amyloid.
His scientific interests lie mostly in Traumatic brain injury, Pharmacology, Internal medicine, Neuroinflammation and Neurodegeneration. Nigel H. Greig has included themes like Inflammation, Excitotoxicity, Programmed cell death, Disease and Neuroscience in his Traumatic brain injury study. Particularly relevant to Neuroprotection is his body of work in Pharmacology.
His research in Internal medicine intersects with topics in Diabetes mellitus, Endocrinology and Oncology. Nigel H. Greig combines subjects such as Prepulse inhibition and Butyrylcholinesterase with his study of Endocrinology. His Neurodegeneration research includes elements of Acetylcholinesterase, Cholinergic, Glucagon-like peptide-1, Microglia and Long-term potentiation.
Nigel H. Greig mainly investigates Neuroinflammation, Traumatic brain injury, Pharmacology, Neurodegeneration and Neuroscience. He studies Neuroprotection, a branch of Pharmacology. His study on Neurodegeneration is covered under Internal medicine.
The study incorporates disciplines such as Diabetes mellitus and Placebo in addition to Internal medicine. His studies in Neuroscience integrate themes in fields like Parkin, Drug development, Disease and Mitochondrion. His work carried out in the field of Endocrinology brings together such families of science as Long-term potentiation and Genetically modified mouse.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent
Nigel H. Greig;Tadanobu Utsuki;Tadanobu Utsuki;Donald K. Ingram;Yue Wang.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease
E F Fang;Y Hou;K Palikaras;B A Adriaanse.
Nature Neuroscience (2019)
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.
Jack T. Rogers;Jeffrey D. Randall;Catherine M. Cahill;Paul S. Eder.
Journal of Biological Chemistry (2002)
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Yazhou Li;Tracy Ann Perry;Mark S. Kindy;Brandon K. Harvey.
Proceedings of the National Academy of Sciences of the United States of America (2009)
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Nigel H. Greig;Tada Utsuki;Qian-sheng Yu;Xiaoxiang Zhu.
Current Medical Research and Opinion (2001)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda;Kate Maclagan;Simon S Skene;Martha Bajwa-Joseph.
The Lancet (2017)
Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Jesse S. Kerr;Bryan A. Adriaanse;Nigel H. Greig;Mark P. Mattson;Mark P. Mattson.
Trends in Neurosciences (2017)
Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.
Margarzata Szayna;Máire E. Doyle;Jennifer A. Betkey;Harold W. Holloway.
Endocrinology (2000)
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Nigel H. Greig;Debomoy K. Lahiri;Kumar Sambamurti.
International Psychogeriatrics (2002)
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4
TracyAnn Perry;Norman J. Haughey;Mark P. Mattson;Josephine M. Egan.
Journal of Pharmacology and Experimental Therapeutics (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Indiana University
Johns Hopkins University School of Medicine
Medical University of South Carolina
National Institutes of Health
Tel Aviv University
Louisiana State University
Harvard University
National Institutes of Health
National Institutes of Health
Harvard University
University of Massachusetts Amherst
Pennsylvania State University
Cornell University
Apple (United States)
University of Strathclyde
Max Delbrück Center for Molecular Medicine
McMaster University
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria
Indiana University
University of Manchester
Children's Hospital of Philadelphia
University of British Columbia
Uniformed Services University of the Health Sciences
The University of Texas at San Antonio
National Endowment for Democracy